Esperion Therapeutics, Inc. (ESPR) Balance Sheet

The company's inability to reverse its negative retained earnings, which stood at -$1.6B as of 2026Q1, suggests that historical capital allocation has not yet translated into a self-funding business model. Investors should monitor whether the recent stabilization in total assets can be sustained without further dilutive financing or significant improvements in operational efficiency.

The volatility in debt levels suggests a reactive approach to capital management, likely driven by the need to maintain liquidity during periods of high cash burn. This reliance on debt, coupled with a negative equity base, implies that the company's financial flexibility is constrained and warrants further investigation into future refinancing risks.

The sharp decline in the current ratio during late 2025 suggests that the company's short-term obligations have periodically outpaced its liquid assets, creating potential pressure on working capital. This inconsistency in liquidity management may indicate that the company is susceptible to sudden shocks in its commercial revenue streams or unexpected increases in operating costs.